Evaluation of the quality control of anticoagulation in patients with atrial fibrillation in a Primary Health Care Area of Madrid

• Published in: Semergen, medicina de familia Vol. 42; no. 5; pp. 287 - 292
• Main Authors: Habashneh Sánchez, S, Abad Díaz, I, Tinajero Valle, C P, Cortés Palmero, A, Lobón Agúndez, M C, Muñoz Fernández, C
• Format: Journal Article
• Language: Spanish
• Published: Spain 01-07-2016
• Subjects: Adult; Aged; Aged, 80 and over; Anticoagulants - therapeutic use; Atrial Fibrillation - drug therapy; Drug Monitoring; Female; Humans; International Normalized Ratio; Male; Middle Aged; Primary Health Care - standards; Quality Control; Quality Indicators, Health Care; Retrospective Studies; Spain; Treatment Outcome; Tiempo en rango terapéutico; Atrial fibrillation; Calidad; Quality; Anticoagulation; Fibrilación auricular; Time in therapeutic range; Anticoagulación
• ISSN: 1578-8865
• DOI: 10.1016/j.semerg.2015.06.009

To calculate the time in therapeutic range (TTR), as well as the scores on the CHADS2 scale in anticoagulated patients with non-valvular atrial fibrillation, attending the Primary Care Health Centre of Aravaca.
Basic health area of Aravaca (Madrid).
Retrospective observational study.
The Community of Madrid provides a list of patients with non-valvular atrial fibrillation and on anticoagulant therapy in the centre. Excluding those with less than 8 INRs, who began treatment after January 2011, interrupted by inter-current treatment or had cancer or coagulopathy. The study period is from 1 January 2012 to 1 January 2013.
The TTR (fraction of INRs in range) was the primary endpoint. The score was also calculated on the CHADS2 scale.
A value of 56.28% TTR (59.5-53.1) was obtained from a sample of 963 INRs. Just over half (52%) of patients had a TTR<60%. There were 65 patients with a mean age of 80±7.5 years. The distribution of risk factors for the CHADS2 scale was: Heart failure 18.5%; hypertension 80%; diabetes 29.2%, and embolic events 18.5%.
The results of our sample TTR is suboptimal (<60%), which implies an increased risk for embolic episodes and increased likelihood of bleeding. We need to incorporate into our clinical practice an objective measure of the quality of anticoagulation in order to identify poorly controlled patients and introduce corrective measures.